Cytosorbents Corporation · NASDAQ:CTSO
Cytosorbents — Investor Presentation (December 2025)
30 slides from Cytosorbents's investor presentation, December 2025
Slide 1: Investor Presentation December 2025
NASDAQ: CTSO Investor Presentation December 2025 1 |
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents Medical, Inc and CytoSorbents Europe GmbH that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actu
Slide 3: CytoSorbents at a Glance
CytoSorbents at a Glance • Platform blood purification technology for removing toxins and harmful substances from the blood • High margin “razorblade” that we manufacture in U.S. - is “plug and play” into existing hospital blood pumps CytoSorb • Treatment of life-threatening conditions in the ICU an
Slide 4: The Power of the Bead
The Power of the Bead Hemocompatible, highly porous polymer bead platform technology that act like tiny sponges to remove harmful substances from blood by pore capture, adsorption, and concentration • Excellent removal of a broad range of substances from whole blood and plasma • Solid state porous p
Slide 5: Products are "Plug and Play" Compatible
Products are “Plug and Play” Compatible Compatible with Existing Blood Pump Infrastructure In Hospitals Today Dialysis or CRRT Hemoperfusion (Continuous Renal Replacement Therapy) (Standalone Treatment) ECMO CPB (Extracorporeal Membrane Oxygenation) (Cardiopulmonary Bypass) 5 | CytoSorbents Confiden
Slide 6: Expanding the Dimension of Blood Purification
Expanding the Dimension of Blood Purification CytoSorb is a powerful blood purification technology that removes a broad range of harmful substances that dialysis does not CytoSorb works like the liver Dialysis works like the kidney Large Molecules and Fat soluble substances Small Molecules and Water
Slide 7: CytoSorb: Our Core Business
CytoSorb Our Core Business 7 |
Slide 8: CytoSorb Controls Massive Inflammation - the Heart of Critical Illness
CytoSorb Controls Massive Inflammation - the Heart of Critical Illness • Acute inflammation is the body’s mechanism to fight injury and infection • However, severe inflammation, driven by cytokine storm, can cause a chain reaction of problems that can end in organ failure and death CAPILLARY IMMUNE
Slide 9: Targets Deadly Conditions That Afflict Millions of People
Targets Deadly Conditions That Afflict Millions of People Critical Care Cardiothoracic Surgery Removes the “fuel to the fire” of massive Reduces inflammation and blood thinners, uncontrolled inflammation that is often targeting reduction in complications of cardiac associated with organ failure and
Slide 10: This is Why CytoSorb Continues To Grow in ICU applications
This is Why CytoSorb Continues To Grow in ICU applications Sepsis, Septic Shock, Liver Cytokine storm/ Other Shock Cytokine release Pancreatitis failure syndrome Infectious diseases Post-surgical Neuroinflammation (flu, COVID-19, other) Burn injury complications Organ transplant Acute Respiratory Hi
Slide 11: Continue to Leverage Clinical Data
Continue to Leverage Clinical Data 11 | * CytoSorb is E.U. approved but not yet Voices around the world cleared or approved in the U.S.
Slide 12: Sepsis and Septic Shock are Deadly
Sepsis and Septic Shock are Deadly • Sepsis is a complex life-threatening condition where the inflammatory response to a serious infection can spiral out of control, fueled by the excessive production of cytokines (cytokine storm), bacterial toxins, and other inflammatory agents • Unchecked, massive
Slide 13: CytoSorbents is Leading a New Era in Sepsis Treatment
CytoSorbents is Leading a New Era in Sepsis Treatment For more than a decade, CytoSorbents has collaborated with clinicians and scientists around the world to advance the treatment of sepsis and septic shock by complementing traditional antibiotics with the broad-spectrum capability of CytoSorb Cyto
Slide 14: CytoSorb Enables Multi-Faceted Attack on Septic Shock
CytoSorb Enables Multi-Faceted Attack on Septic Shock A wealth of published, peer-reviewed studies support the broad mechanisms of action of CytoSorb that enable a comprehensive and multi-faceted attack on septic shock – from beginning to end CytoSorb helps to achieve the Core Treatment Goals in Sep
Slide 15: The Key to Success: Right Patient, Right Timing, Right Dosing
The Key to Success: Right Patient, Right Timing, Right Dosing Right Patient Just like antibiotics, CytoSorb works most effectively when: Highest • Treat Early Chance for • Treat Intensively Good Cinical • Compete the Full Course of Treatment Outcome Right Right Timing Dose 15 | * CytoSorb is E.U. ap
Slide 16: 2025: COSMOS Registry Highlights Treatment Strategy Success
2025: COSMOS Registry Highlights Treatment Strategy Success COSMOS registry, patient characteristics CAPILLARY LUNG • Data from 150 patients analyzed SHOCK LEAK FUNCTION • Critical care indications: Septic shock (57.6%) Cardiogenic shock (12.9%) Rhabdomyolysis (10.6%) Acute/acute-on-chronic liver fa
Slide 17: 2025: Early & Intensive Treatment with More Blood Treated Works Best
2025: Early & Intensive Treatment with More Blood Treated Works Best • Large, retrospective single center study • 175 patients with septic shock treated with CytoSorb • Evaluated the impact of early versus late, and low versus high intensity treatment with CytoSorb on mortality compared to predicted
Slide 18: CytoSorb Improves Survival in Septic Shock Meta-Analysis
CytoSorb Improves Survival in Septic Shock Meta-Analysis • Meta-analysis of 744 septic shock patients from 1 RCT and 8 observational studies from 2019-2024, of which 449 patients were treated with CytoSorb • CytoSorb reduced in-hospital mortality (OR 0.64, p=0.04) • 28-30-day mortality was also halv
Slide 19: Turning the Tide of Sepsis and Septic Shock: Real World Insights with CytoSorb
Turning the Tide of Sepsis and Septic Shock: Real World Insights with CytoSorb September 10, 2025 Link to webinar replay: https://cyto.news/webinar-sepsis/sep10 19 |
Slide 20: The Opportunity of DrugSorb-ATR
The Opportunity of 20 | * The DrugSorb-ATR system is an investigational device that is not yet cleared/approved by FDA, Health Canada, or by any other Global Regulatory Agency and is not commercially available for sale
Slide 21: Blood Thinners Can Cause Serious Perioperative Bleeding
Blood Thinners Can Cause Serious Perioperative Bleeding DrugSorb-ATR can help • Millions of people are on blood thinners to reduce their risk of heart attack and stroke • Acute heart attack patients commonly receive “super-aspirin” blood thinners like Brilinta® to improve clinical outcomes • But Bri
Slide 22: Brilinta and the Use Case for DrugSorb-ATR
® Brilinta and the Use Case for 5 - 10% will need open heart surgery The ultimate goal of DrugSorb-ATR is to allow patients to get the critical surgery they need without X X XX X delay, while reducing or preventing 22 | bleeding complications
Slide 23: DrugSorb-ATR is De Novo Eligible
DrugSorb-ATR is De Novo Eligible • U.S & Canadian randomized controlled STAR-T trial established DrugSorb-ATR as a De Novo 510(k) eligible device, DrugSorb-ATR must show that its probable benefits outweigh its probable risks to gain market clearance • Our initial De Novo submission that was reviewed
Slide 24: FDA Regulatory Timeline
FDA Regulatory Timeline • On November 7, 2025, we filed a formal Pre-Submission Meeting Request with supporting documentation • Anticipate a pre-submission meeting will be held in either late 2025 or early Q1 2026 to confirm FDA requirements for the new De Novo application • Expect to file a new De
Slide 25: Financial Performance
25 Financial Performance CytoSorbents.
Slide 26: CytoSorb Commercialization Focus
CytoSorb Commercialization Focus • We sell CytoSorb in more than 70 countries worldwide with nearly 300,000 treatments to date • Sell Direct in Germany and 8 other countries & through Distributors and partners in the remainder Estimated Revenue By Market Revenue By Geography Other Critical Care: 17%
Slide 27: Core Business Performance Summary
Core Business Performance Summary • Q3 2025 Revenue was $9.5M, a 10% increase vs $8.6M a year ago • Performance led by record sales in our distributor territories, and strong sales in our other direct markets • Aided by favorable currency exchange • Currently undergoing a restructuring of our German
Slide 28: Targeting Acceleration of Annual Revenue Growth
Targeting Acceleration of Annual Revenue Growth Trailing 12-month revenue (as of 9/30/25) was $45.0 Annual Product Sales $37.0M vs $33.8M in the comparable period a year $40.0 $39.5M $40.1M $37.0M ago $6.3 $9.4 $35.6M $37.0 $35.0 $35.6 $33.8 $31.1M* $30.0 $29.4M* • Distributor/Partner sales: $15.6M
Slide 29: A Clear and Compelling Value Proposition
A Clear and Compelling Value Proposition We believe CytoSorbents is significantly undervalued. We continue to execute our strategy designed to drive strong future growth and reduce risk. With expected sequential progress in our business, our goal is to improve operational visibility, attract new inv
Slide 30: CytoSorbents Corporation
CytoSorbents Corporation NASDAQ: CTSO Company Contact: Dr. Phillip Chan pchan@cytosorbents.com www.cytosorbents.com 30